All In Biotech

Drug Trial Radar · NCT00321672

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

Last checked: Nov 20, 2026Latest source record: Jun 14, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 494 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

494

Actual

Start

Jun 2006

Primary completion

Dec 2007

Study completion Dec 2007

Sponsor

Lead sponsor
NeurogesXIndustry
Sponsor type
Industry
First posted
May 4, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study was to assess the efficacy and safety of NGX-4010 applied for 30 or 60 minutes for the treatment of painful HIV-associated neuropathy.

Conditions

  • Pain
  • HIV Infections
  • Peripheral Nervous System Diseases

Interventions

  • NGX-4010, 8% capsaicin patchDrug

    Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.

  • 0.04% capsaicin patchDrug

    Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.

  • NGX-4010, 8% capsaicin patchDrug

    Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.

  • 0.04% capsaicin patchDrug

    Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Primary Measure of Efficacy Was the Percent Change in the "Average Pain for the Past 24 Hours" Numeric Pain Rating Scale (NPRS) Score From Baseline During Weeks 2 to 12.Time frame: Weeks 2-12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.